Pharmacologic eIF2B Activation Rescues Neuropathy in CMT2 Subtypes by Normalizing the Integrated Stress Response

Verdict. Among the many subtypes of Charcot–Marie–Tooth (CMT) disease, several result from mutations in genes encoding aminoacyl–tRNA synthetases, enzymes required for tRNA charging during cytoplasmic and mitochondrial translation. It intersects mitochondrial stress/dysfunction themes (molecular/genetic defect; disease context; neurodegeneration).

What the authors report

RTX–117, a CNS-penetrant small molecule currently in Phase 1 clinical trials, targets eukaryotic initiation factor 2B (eIF2B), a key modulator of protein synthesis and the ISR pathway. In GarsP278KY/+ mice, which develop early onset motor defects and axonal pathology that recapitulate CMT2D symptoms from tRNA synthetase mutations, RTX–117 treatment started after disease onset reduced chronic ISR activation and produced significant functional and electrophysiological improvement.

Key results stated in the abstract include the following. Among the many subtypes of Charcot–Marie–Tooth (CMT) disease, several result from mutations in genes encoding aminoacyl–tRNA synthetases, enzymes required for tRNA charging during cytoplasmic and mitochondrial translation. We report that activation of the integrated stress response (ISR) pathway is a shared molecular feature of tRNA synthetase–associated and other axonal CMT subtypes. Using cryo–EM studies, we have characterized the binding mode of RTX-117 to the eIF2B decamer.

Why it matters for mitochondrial biology

Within mitochondrial research, this work maps primarily to redox biology, therapeutics, computational. It is relevant to mitochondrial dysfunction discourse because the abstract invokes molecular/genetic defect, disease context, neurodegeneration. That does not by itself establish a validated disease mechanism; it indicates thematic proximity. Because a therapeutic or interventional angle is present, the piece is of interest for mitochondrial-targeted drug hypothesis generation—subject to full-text validation of endpoints and safety context. Causal language appears in the abstract; such claims should be treated as provisional until design details (loss-of-function, rescue, dose-response) are verified. Server: biorxiv. Posted 2026-08-06. Synthesis confidence is bounded by abstract completeness.

Study design (abstract-level)

In GarsP278KY/+ mice, which develop early onset motor defects and axonal pathology that recapitulate CMT2D symptoms from tRNA synthetase mutations, RTX–117 treatment started after disease onset reduced chronic ISR activation and produced significant functional and electrophysiological improvement. Broader surveillance of the ISR pathway across models of neurodegeneration reveals strong activation in several diseases and a correlation with disease progression, particularly in models of Alzheimer's disease. These findings identify chronic ISR activation as a recurrent, though not universal, pathological mechanism of neurodegenerative disease models.

Principal findings

1. Among the many subtypes of Charcot–Marie–Tooth (CMT) disease, several result from mutations in genes encoding aminoacyl–tRNA synthetases, enzymes required for tRNA charging during cytoplasmic and mitochondrial translation.
2. We report that activation of the integrated stress response (ISR) pathway is a shared molecular feature of tRNA synthetase–associated and other axonal CMT subtypes.
3. Using cryo–EM studies, we have characterized the binding mode of RTX-117 to the eIF2B decamer.
4. We further identify ISR targets, including secreted proteins such as GDF15 and FGF21 that may serve as translational biomarkers for treatment response to RTX–117 in CMT disease.
5. Overall, our study identifies candidate biomarkers for CMT disease subtypes associated with defects in translational homeostasis and supports eIF2α–ATF4 axis modulation as a promising therapeutic strategy for this disease class.

Limitations of this brief

• This Mitos brief is an abstract-level synthesis of a preprint; it is not peer review and not a substitute for reading the full paper.
• Preprint status: findings may change with revision or journal review.
• Effect sizes, n numbers, statistics, and full experimental controls are typically incomplete at abstract resolution.
• Comparator/control language is weak or absent in the abstract, limiting causal inference from this brief alone.
• Primary source: biorxiv DOI 10.64898/2026.08.05.743063 (posted 2026-08-06).

Open scientific questions

• Which specific experimental panels in the full paper establish the strongest causal claim, and how robust are the controls?
• What dose, timing, and off-target profile would be required to take the intervention seriously as a therapeutic hypothesis?
• How do these findings sit relative to prior literature on the same pathway—replication, contradiction, or incremental extension?

Bottom line

For mitochondrial biologists focused on redox biology, therapeutics, computational, this preprint is worth full-text review soon. Abstract-level takeaway: Among the many subtypes of Charcot–Marie–Tooth (CMT) disease, several result from mutations in genes encoding aminoacyl–tRNA synthetases, enzymes required for tRNA charging during cytoplasmic and mitochondrial translation. Confirm methods, effect sizes, and controls in the full PDF before citing the result as established.

Bibliographic record

Abstract-based editorial synthesis by Mitos. Not peer review.